Related references
Note: Only part of the references are listed.Constitutive expression of IL-12Rβ2 on human multiple myeloma cells delineates a novel therapeutic target
Irma Airoldi et al.
BLOOD (2008)
Interleukin-2, interleukin-12, and interferon-γ levels and risk of young adult Hodgkin lymphoma
Wendy Cozen et al.
BLOOD (2008)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Lauren W. Collison et al.
NATURE (2007)
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
Andres O. Soriano et al.
BLOOD (2007)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Methylation of the IL-12Rβ2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells
I Airoldi et al.
CANCER RESEARCH (2006)
Novel nonviral delivery approaches for interleukin-12 protein and gene systems: Curbing toxicity and enhancing adjuvant activity
Mohamed Labib Salem et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2006)
Lack of Il12rb2 signaling predisposes to,spontaneous autoimmunity and malignancy
I Airoldi et al.
BLOOD (2005)
DNA methyltransferase inhibitors and the development of epigenetic cancer therapies
F Lyko et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Characterization of DNA demethylation effects induced by 5-aza-2′-deoxycytidine in patients with myelodysplastic syndrome
C Mund et al.
CANCER RESEARCH (2005)
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
MF Fraga et al.
NATURE GENETICS (2005)
Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: Clinical efficacy
L Heinzerling et al.
HUMAN GENE THERAPY (2005)
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
JPJ Issa et al.
BLOOD (2004)
Drug therapy: Multiple myeloma
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
JG Herman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
New insights into the pathophysiology of multiple myeloma
S Seidl et al.
LANCET ONCOLOGY (2003)
The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses
G Trinchieri et al.
IMMUNITY (2003)
Role of the bone marrow microenvironment in multiple myeloma
GD Roodman
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases
L Zhou et al.
JOURNAL OF MOLECULAR BIOLOGY (2002)
Interleukin-12 in anti-tumor immunity and immunotherapy
MP Colombo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
IL-6 transgenic mouse model for extraosseous plasmacytoma
AL Kovalchuk et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature
C Halin et al.
NATURE BIOTECHNOLOGY (2002)
Epigenetic reprogramming in mammalian development
W Reik et al.
SCIENCE (2001)
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer
SB Baylin et al.
HUMAN MOLECULAR GENETICS (2001)
Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study
WK Kang et al.
HUMAN GENE THERAPY (2001)
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
MS Soengas et al.
NATURE (2001)
Expression and function of IL-12 and IL-18 receptors on human tonsillar B cells
I Airoldi et al.
JOURNAL OF IMMUNOLOGY (2000)
IL-12 receptor β2 (IL-12Rβ2)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites
CY Wu et al.
JOURNAL OF IMMUNOLOGY (2000)
Low-dose 5-aza-2 '-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
P Wijermans et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent
MJ Smyth et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
